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The transcription factor IRF4 is known to be essential for differentiation of effector CD4+ T cell subsets.
In this issue, Yao et al. (2013) identify IRF4 as a regulator of checkpoints in the final steps and maintenance
of CD8+ T cell effector differentiation.The transcription factor IRF4 belongs to
the family of interferon regulatory factors
(IRFs) consisting of nine members in
miceandhumans that play important roles
in the regulation of innate and adaptive im-
mune responses aswell as in oncogenesis
(Biswas et al., 2010). IRF4 has long been
known to be essential for differentiation
of the effector CD4+ T helper cell subsets
Th2, Th9, Th17, and Tfh (Biswas et al.,
2010; Bollig et al., 2012; Bru¨stle et al.,
2007; Staudt et al., 2010). This IRF4
dependence is reflected by the total resis-
tanceof IRF4-deficientmice to diseases in
which these cells are pathogenic such as
allergic asthma, experimental allergic
encephalomyelitis (EAE), and inflamma-
tory bowel disease. Along these lines, it
has been shown that IRF4 cooperates
with BATF-JUN transcription factor heter-
odimers for binding to AP-1-IRF4 com-
posite elements (AICE), as reviewed in
detail in Murphy et al. (2013). Upon bind-
ing, chromatin modifications occur that
allow in a second step the access of the
Th17-cell-specific transcription factor
RORgt. Possibly, similar modifications
also permit binding of other subset-
specific transcription factors like GATA-3
in the respective Th cell subsets.
Earlier this year, it was described that
IRF4 is also required for the development
of IL-17-producing CD8+ T (Tc17) cells
(Huber et al., 2013). In this context,
IRF4 regulated Tc17 differentiation by
increasing the amounts of transcription
factors crucial for type 17 helper cell
differentiation (RORgt and RORa) on
one hand and by decreasing transcription
factors regulating alternative fates, like
regulatory T (Treg)-cell-specific Foxp3
and cytotoxic T lymphocyte (CTL)-spe-
cific eomesodermin (Eomes), on the other.
Importantly, a function of CD8+ T cellsbeyond normal text book knowledge
became obvious, because IRF4-sufficient
Tc17 cells provided ‘‘reverse help’’ via
cell-associated IL-17A to CD4+ T cells for
Th17-cell-mediated encephalomyelitis.
Three parallel papers from Yao et al.
(2013) (in this issue of Immunity), our
own group (Raczkowski et al., 2013),
and the group of Kallies (Man et al.,
2013) now describe that IRF4 is also
crucial for the sustained expansion and
effector function of cytotoxic CD8+
T lymphocytes. It is current knowledge
that upon infection with intracellular
pathogens, specific CD8+ T cells become
activated in peripheral lymphatic organs,
proliferate, and differentiate into CTLs.
Upon antigen encounter in peripheral tis-
sue, these effector CD8+ T cells produce
inflammatory cytokines and are endowed
with the property to kill infected cells.
After resolution of infection, the bulk of
CTLs dies; however, a small fraction
persists as long-lived memory cells that
respond with strong proliferation and
rapid reconversion into effectors upon
re-exposure to the cognate pathogen.
The phenotypic and functional changes
toward effector and memory differentia-
tion are regulated by gradual expression
of several transcription factors. Whereas
Bcl6, Eomes, Id3, and TCF1 are associ-
ated with memory cell differentiation and
longevity of cells, T-bet, Id2, and Blimp-1
promote effector cell development (Kaech
and Cui, 2012).
By using low- andhigh-affinity peptides,
Yao et al. (2013) elegantly demonstrate
that IRF4 expression in CD8+ T cells criti-
cally depended on the strength of the
T cell receptor (TCR)-ligand interaction
and on mammalian target of rapamycin
(mTOR) activity. Thus, strong TCR
signaling induced high IRF4 expressionImmunity 39, Nand this correlated with elevated activity
of mTOR; conversely, inhibition of the
mTOR pathway caused downregulation
of IRF4. Because IRF4 expression has
been shown to depend on interleukin-2
(IL-2)-inducible T cell kinase (ITK), the au-
thors used inhibitors for both ITK and
mTOR and demonstrated that these two
signaling pathways seemed to cooperate
for IRF4 induction. The relevance of IRF4
for CD8+ T cell function was studied in
mice with conditional deletion of IRF4 in
CD8+T cells. Thegenetic ablation strategy
caused IRF4 deletion mostly in mature
CD8+ T cells and had no relevant influence
on CD4+ T cells. In this system, IRF4
expression in CD8+ T cells was important
for clearance of influenza infection as
well as for recovery from disease. As
compared to WT counterparts, IRF4-defi-
cient CTLs proliferated less, were more
prone to apoptosis, and produced fewer
effector molecules crucial for viral clear-
ance such as Granzyme B and inter-
feron-g (IFN-g). Complementary to these
data, our group has shown in another in-
fectious model that IRF4-deficient mice
cannot clear the intracellular bacterial
pathogen Listeria monocytogenes, also
because of intrinsic defects in CD8+
T cell expansion and effector function
(Raczkowski et al., 2013). Lack of main-
tained CD8+ T cell effector function in the
absence of IRF4 is also demonstrated in
the third mentioned study (Man et al.,
2013).
To gain mechanistic insights into how
IRF4 regulates antiviral CD8+ T cell
immune responses, Yao et al. (2013)
coculturedCD8+Tcells anddendritic cells
in vitro. Similar to us, they found that early
after activation, IRF4-deficient CD8+
T cells expanded and displayed normal
expression of the activation markersovember 14, 2013 ª2013 Elsevier Inc. 797
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Figure 1. Relationship between Strength of TCR Ligation, IRF4 Expression, and the
Development of Effector CD8+ T Cells
Strong TCR ligation causes increased mTOR activity, high expression of IRF4 and Blimp-1, and highly
active aerobic glycolysis in CD8+ T cells. IRF4 enables maintained expansion and differentiation into
effector CD8+ T cells characterized by high expression of the surface markers CD44 and CD25 and
the effector molecules GzmB and IFN-g. These effector cells efficiently clear infections with intracellular
pathogens. In contrast, suboptimal TCR signaling causes lower mTOR activity and low IRF4 as well as
Blimp-1 expression. Such nonproductively activated CD8+ T cells still express CD44 and CD25 but
perform only limited glycolysis and fail to maintain proliferation and differentiation into effector cells.
These cells express GzmB and IFN-g at low amounts, fail to clear pathogens, and enable development
of chronic infection.
Immunity
PreviewsCD69 and CD25, as well as of the effector
molecules IFN-g and Granzyme B. How-
ever, maintenance of proliferation was
severely hampered, effector differentia-
tion failed to proceed, and cell death was
enhanced. All these defects were rescued
by overexpression of IRF4, which ex-
cludes developmental alterations of
IRF4-deficient CD8+ T cells prior to
effector cell differentiation. When
analyzing the molecular mechanisms
of how IRF4 sustains the expansion of
CD8+ T cells, Yao et al. (2013) found that
IRF4 repressed several cyclin-dependent
kinase inhibitors (such as Cdkn2a,
Cdkn1a, and Cdkn1c) and directly bound
to the Cdkn2a locus. As for CD8+ T cell
survival, chromatin immunoprecipitation
(ChIP) analysis suggests that IRF4 directly
inhibited the expression of the proapopto-
tic geneBim.However, apoptosis of IRF4-
deficient CD8+ T cells can not solely be
attributed to regulation of Bim expression,
because in the thirdmentioned study, Bim
deletion fails to rescue the phenotype
(Man et al., 2013). Thus, with respect to
proliferation and survival, IRF4 may oper-
ate as a transcriptional inhibitor of cyclin-
kinase inhibitors and proapoptotic genes.
In contrast, during effector differentiation,
IRF4 seems to play amore indirect role, as
demonstrated by Yao et al. (2013). Here,
IRF4 induced expression and function of
other transcription factors crucial for
CD8+ T cell effector generation, such as798 Immunity 39, November 14, 2013 ª2013Blimp1, T-bet, and HIF1a. Furthermore,
IRF4 mediated histone modification and
alteration of T-bet binding to the pro-
moters of the effector molecules Gzmb
and Ifng. As for the effects on the Blimp-1
protein encodedbyPrdm1, theywere also
reported by Raczkowski et al. (2013) and
are reminiscent to similar functions of
IRF4 in B and CD4+ T cells. Moreover,
IRF4 seems to support CD8+ T cell
effector differentiation also by controlling
glucose metabolism and glycolysis via
the HIF complex. This is the result of the
third mentioned study (Man et al., 2013),
which elegantly identifies roles of IRF4
not only on Hif1a and Foxo1, transcription
factors regulating metabolic pathways,
but also on the expression of glucose
transporters and several molecules
involved in glycolysis. Thus, IRF4 is essen-
tial for high glycolytic turnover to provide
the energy for CD8+ T cell growth and dif-
ferentiation. However, low glycolysis in
IRF4-deficient CD8+ T cells could also be
an indirect consequence of proliferative
breakdown and increased apoptosis.
Therefore, this very interesting hypothesis
needs further elucidation and confirma-
tion. Furthermore, Man et al. (2013) show
that most IRF4-binding sites in CD8+
T cells are AP1-IRF4 composite motifs,
as previously demonstrated for CD4+
T cells (Murphy et al., 2013). Shared and
individual effects of IRF4 and BATF in
CD8+ T cells have also been studied byElsevier Inc.Yao et al. (2013). When comparing the
phenotype of BATF- and IRF4-deficient
CD8+ T cells, these authors found that
IRF4 and BATF defects overlapped only
partially. Obviously, survival of CD8+
T cells is cooperatively regulated by both
IRF4 and BATF, whereas in contrast the
expansion of CD8+ T cells seems to be
mediated by IRF4 in a BATF-independent
manner.
Taken together, the three recently
published reports consistently show
that expression of IRF4 in CTLs depends
on the strength of TCR ligation. Although
dispensable for early activation events as
measured by phenotypical changes, pro-
liferation, and cytokine production, IRF4
is essential for the maintenance of CTL
properties and thus for establishment
of a fully functional effector and also
memory pool. IRF4 seems to regulate
these functions at several levels, acting
as both transcriptional repressor and
activator. The three studies agree that
the direct positive regulation of Prdm1
gene expression contributes to the IRF4
effects. The study by Yao et al. (2013)
includes the regulation of cyclin-kinase
inhibitors, antiapoptotic molecules, and
T-bet and chromatin modifications to
the spectrum of IRF4 targets in differen-
tiating effector CD8+ T cells. The study
by Man et al. (2013) suggests an impor-
tant role of IRF4 in the regulation of
cellular metabolic pathways. Thus, IRF4
has central basic functions and also
context-dependent functions, such as
during T cell subset differentiation (e.g.,
Tc17 and Th17), which may be regulated
by diverse cooperating transcription fac-
tors. Furthermore, all three reports
clearly suggest that IRF4 can be used
as a reliable marker of successful CTL
differentiation and also as a target
(Figure 1). One could speculate that by
upregulation of IRF4 expression, e.g.,
via high-affinity ligands, it will be possible
to boost CTL effector function and mem-
ory formation, for example against tumor
antigens or during vaccination. On the
other hand, artificial downregulation of
IRF4 expression via low-affinity peptides
may be a means to downregulate
chronic CTL-mediated inflammations. At
any rate, it is now apparent that IRF4
represents a staple ingredient in the ra-
tions available to CD8+ T cells going
into the theater of combat and into
harm’s way.
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A study by Figueiredo et al. (2013) in this issue of Immunity demonstrates that administration of anthracy-
clines induces autophagy in vivo and has a powerful protective effect in a mouse model of sepsis.Septic shock remains one of the most
formidable problems in critical-care
medicine (Rittirsch et al., 2008). It is typi-
cally caused by bacteremia and the
ensuing systemic inflammatory response
to infection. Some patients can gradually
recover and survive the ordeal. Sadly,
many reach a tipping point whereupon
they sink into an ultimately lethal down-
ward spiral of cascading failures of multi-
ple tissues and organs. An early aggres-
sive antibiotic treatment to control the
infection is essential but often insufficient
to prevent a lethal outcome. The mortal-
ity rate depends on the timing of antibi-
otic administration, but other than that,
it is not entirely clear why some patients
manage to recover while others get tip-
ped over the edge and quickly become
impossible to save. Needless to say,
the puzzle of septic shock has haunted
clinicians and basic scientists for de-
cades as efficient therapies for this
deadly condition have remained unavai-
lable (Iskander et al., 2013). A study by
Moita and colleagues in this issue of
Immunity describes an unexpected and
powerful therapeutic effect of anthracy-clines in a mouse model of polymicrobial
sepsis.
In this study, Figueiredo et al. used a
chemical screen to identify compounds
with anti-inflammatory properties. Among
the inhibitors they identified are epiru-
bicin, doxorubicin, and daunorubicin,
the anthracycline family drugs used
for chemotherapy of several cancers.
Anthracyclines cause DNA damage by
intercalating between base pairs and by
inhibiting topoisomerase II, the enzyme
involved in relaxing supercoiled DNA
(Minotti et al., 2004). These effects result
in inhibition of DNA replication, cell-cycle
arrest, and apoptosis of proliferating cells.
Figueiredo et al. used a cecal ligation and
puncture (CLP) model of sepsis to test the
effect of anthracyclines on bacteremia
and sepsis progression. Surprisingly,
they found that anthracycline adminis-
tration at the time of the CLP procedure
dramatically improved the survival of
mice without affecting bacterial burden.
This indicated that anthracyclines pro-
moted organ protection from sepsis, a
conclusion supported by the reduction
of several markers of organ damagein anthracycline - treated mice. As ex-
pected, administration of a broad spec-
trum antibiotic (meropenem) resulted in
a strong reduction of bacterial burden,
but although this delayed CLP-induced
mortality, it did not prevent it. Impor-
tantly, both epirubicin (anthracycline)
and meropenem (antibiotic) administra-
tion suppressed production of inflamma-
tory cytokines, including interleukin-1,
tumor necrosis factor, and high-mobility
group box 1. This indicated that reduced
cytokine production observed in epirubi-
cin-treated mice is not sufficient to
prevent mortality, suggesting that the
effects of anthracyclines cannot be
entirely explained by their anti-inflamma-
tory properties and that they might work
by promoting tissue protection from in-
flammatory damage.
These findings illustrate the distinct
contribution of tissue protection in host
defense against infection. Resistance
and tolerance are two strategies the host
canuse to survivean infection—the former
reduces pathogen burden, and the latter
minimizesdamage causedby agiven level
of infection without directly targeting theovember 14, 2013 ª2013 Elsevier Inc. 799
